23 results about "Psoriatic disease" patented technology

The invention is related to methods of treatment of active psoriatic arthritis (PsA). In certain embodiments, the invention provides pharmaceutical compositions of izokibep and uses thereof for treatment of active psoriatic arthritis.

This invention relates to double-stranded oligonucleotides complementary to JAK1 that result in the regulation of JAK1 expression. Regulation of JAK1 expression is beneficial for a range of medical disorders, including inflammatory bowel disease, organ transplant rejection, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriasis, dermatitis, diabetic nephropathy, systemic lupus erythematosus (SLE), dry eye disease, cancer, myelofibrosis, and asthma. The invention also includes compositions comprising double-stranded oligonucleotides and therapeutic methods using double-stranded oligonucleotides.

The present invention pertains to a method or a pharmaceutical composition of new ovatodiolide derivative compounds, AR100-RA1-Cys and AR100-RA1-ST, which have shown unexpected effects in treating autoimmune diseases, characterized by hepatocellular inflammation, such as autoimmune hepatitis, diabetes mellitus type 1, Sjogren's syndrome, multiple sclerosis and psoriasis. Also provided are the synthetic processes for compound preparation.

This specification discloses FABP inhibitor compounds and their use in pharmaceutical compositions for treating diseases that highly express any of these FABPs, including cancers, particularly triple-negative breast cancer (TNBC), and other pro-inflammatory diseases, including cardiovascular diseases, obesity or obesity-related disorders, diabetes, dyslipidemia, impaired glucose tolerance or impaired fasting blood glucose, vitiligo, psoriasis, autoimmune disorders, pain, and dementia. This specification also discloses methods for preparing the disclosed compounds.

This disclosure relates to compounds of formula I (wherein X and R1-R4, n and m have the meanings set forth herein) and pharmaceutically acceptable salts thereof. Compounds of formula I exhibit GPR183 antagonist activity and are therefore useful in the treatment or prevention of disorders, conditions or diseases for which GPR183 antagonists have been shown to be useful, such as chronic pain, e.g., osteoarthritis, chronic low back pain, neuropathic pain, and immune system disorders, e.g., inflammatory bowel diseases such as colitis and Crohn's disease, multiple sclerosis, rheumatoid arthritis, inflammatory lung diseases, e.g., asthma, and psoriasis. TIFF2026522963000085.tif2570

The present invention relates to a method for producing an ustekinumab antibody in CHO cells. It further relates to the use of the produced antibody in the treatment of plaque psoriasis, psoriatic arthritis and inflammatory bowel disease.

The disclosure herein relates to the development and production of novel antibodies and antigen-binding fragments thereof that bind to TL1A and are useful in the treatment, prevention, and diagnosis of diseases, disorders, or inflammation, including, for example, autoimmune diseases, including rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, systemic lupus erythematosus, asthma, ulcerative colitis, Crohn's disease, psoriasis, primary biliary cirrhosis, primary biliary cholangitis, ankylosing spondylitis, and fibrosis, including intestinal fibrosis, pulmonary fibrosis, and liver fibrosis. Some of the elements of the final antibody structure are designed de novo by a computer system and its data training set, without reference to a particular reference molecule.

The application relates to the technical field of animal models, and discloses a construction method and application of an ectopic ossification arthritis animal model. 91‑115 After being mixed and emulsified with chicken type II collagen as an antigen, animals are immunized to obtain the animal model, which is referred to as a C2V7 model. The arthritis model constructed by the application has high success rate, short time consumption and easily-obtained modeling materials. The model can simulate the onset process of arthritis with obvious ectopic ossification characteristics such as ankylosing spondylitis, enthesial-related arthritis and psoriatic arthritis, objectively reflects the pathological process and pathological characteristics of ectopic ossification arthritis, and provides a new research platform for related research.

The application discloses a nucleic acid aptamer of LL37 antibacterial peptide and a preparation method and application thereof. The nucleic acid aptamer screened by the application has good affinity with antibacterial peptide LL37, can be used for detecting LL37, and provides a new candidate tool for diagnosing psoriasis, systemic lupus erythematosus and other autoimmune diseases based on an LL37 target.

The present invention relates to methods of diagnosing or prognosing arthritis, specifically methods of diagnosing or prognosing psoriatic arthritis. Also disclosed are methods of diagnosing or prognosing rheumatoid arthritis, and methods of differentiating psoriatic arthritis from rheumatoid arthritis. Specifically, the methods involve determining the quantitative or qualitative level of one or more biomarkers in a biological sample from a subject.

Provided are crystal forms of Zasocitinib and methods for preparing them, pharmaceutical compositions containing the crystal form, and the use of the crystal form in the preparation of TYK2 inhibitor drugs and drugs for treating psoriasis, psoriatic arthritis, inflammatory bowel disease and other autoimmune diseases.

The application belongs to the technical field of chemical medicines, and provides a fused ring compound, a preparation method and application thereof. The compound provided by the application can effectively regulate the activity of human TNF alpha, and can be used for treating or preventing rheumatoid arthritis and psoriasis.

This disclosure relates to a method for treating psoriasis vulgaris, comprising administering the anti-IL-23p19 antibody hum13B8-b to a patient in need thereof. This disclosure also relates to a pharmaceutical composition of the anti-IL-23p19 antibody hum13B8-b or its antigen-binding fragment for the treatment of psoriasis vulgaris in a patient. This disclosure further relates to the use of the anti-IL-23p19 antibody hum13B8-b or its antigen-binding fragment for the manufacture of a pharmaceutical product for the treatment of psoriasis vulgaris in a patient. In some embodiments, the Disclosure relates to methods, pharmaceutical compositions, and pharmaceuticals for treating psoriasis vulgaris, wherein the treatment results in the patient maintaining a physician's global assessment (PGA) score of “clear” or “nearly clear,” with a reduction of at least 2 points from baseline, or the patient maintaining at least a 50% reduction in the Psoriasis Area and Severity Index (PASI 50), or the patient maintaining at least a 75% reduction in the Psoriasis Area and Severity Index (PASI 75), or the patient maintaining at least a 90% reduction in the Psoriasis Area and Severity Index (PASI 90), or the patient maintaining a 100% reduction in the Psoriasis Area and Severity Index (PASI 100), for at least about 60 weeks to at least about 432 weeks. In some embodiments, the disclosure relates to methods, pharmaceutical compositions, and pharmaceuticals for treating psoriasis vulgaris, wherein the treatment prevents the patient from experiencing an increase in adverse events (AEs), drug-related AEs, severe adverse events (SAEs), Tier 1 AEs, or Tier 2 AEs for at least about 60 weeks to at least about 432 weeks.

Use of compounds of formula I and formula II, and specifically relates to use of compound A1-A52, B1-B5, or C1-C36 in the preparation of a drug for treating and / or preventing an inflammatory or immune disease are provided. Compounds of A1-A52, B1-B5, or C1-C36 are used in the preparation of a drug for treating and / or preventing diseases such as rheumatoid arthritis, atopic dermatitis, hidradenitis suppurativa, vitiligo, dermatomyositis, alopecia areata, urticaria, multiple myositis, an interstitial lung disease, systemic lupus erythematosus, systemic sclerosis, and psoriasis.

The present invention relates to methods of treating inflammatory diseases, including methods of treating IL-23 associated diseases, in particular inflammatory diseases such as psoriasis, psoriatic arthritis or axial (spinal) spondyloarthritis (ax-SpA), including ankylosing spondylitis and radiographic negative ax-SpA, using anti-IL-23A antibodies.

The present invention relates to compounds that are peptide inhibitors of interleukin-23 receptor (IL-23R) and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including inflammatory diseases, such as inflammatory bowel disease, such as Crohn's disease or ulcerative colitis, psoriasis and psoriatic arthritis. Compounds of the invention exhibit good physical and chemical stability in the gastrointestinal tract.

The present invention relates to double stranded oligonucleotides that are complementary to JAK1, leading to modulation of the expression of JAK1. Modulation of JAK1 expression is beneficial for a range of medical disorders including dry eye disease, inflammatory bowel disease, organ transplant rejection, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriasis, dermatitis, diabetic nephropathy, systemic lupus erythematosus (SLE), cancer, myelofibrosis, and asthma. Also included are compositions comprising the double stranded oligonucleotide and methods of treatment using the double stranded oligonucleotide.

The present invention pertains to method or pharmaceutical composition of new compounds, AR100-RA1-Cys and AR100-RA1-ST, which have unexpectedly effects in treating auto-immune disease caused by hepatocellular inflammation or psoriasis. Also provided are the preparation processes of the compounds.

The present invention provides novel small-molecule compounds with tumor necrosis factor-alpha (TNF-α) and interleukin-17 (IL-17) inhibitory properties, intended for oral administration in the treatment of inflammatory and autoimmune diseases, such as psoriasis and rheumatoid arthritis. These compounds selectively inhibit TNF-α and IL-17, key cytokines implicated in chronic inflammation and immune dysregulation. The compounds of this invention overcome these limitations by offering an orally administrable, cost-effective alternative with high specificity and reduced toxicity. The synthetic methods for preparing the compounds, as well as pharmaceutical formulations are also disclosed.

This disclosure relates, in general, to a process for preparing compounds that are inhibitors of the kinase IRAK4, and to synthetic intermediates prepared thereby. IRAK4 inhibitors may be useful in the treatment of inflammatory and fibrous disorders, such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), gout, Lyme disease, arthritis, psoriasis, pelvic inflammatory disease, systemic lupus erythematosus (SLE), Sjögren's syndrome, inflammation associated with gastrointestinal infections including C. difficile, viral myocarditis, acute and chronic tissue injury, non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, and renal diseases, including chronic kidney disease and diabetic kidney disease.

A therapeutic wearable device is disclosed that uses a plurality of different frequencies from the electromagnetic spectrum including frequencies from the visible region, the IR region, the radio region and optionally low frequency vibrational therapy. The therapeutic wearable device can be used to treat any of a plurality of conditions such as depression, seasonal affective disorder, sleep disorders, circadian rhythm disorders, psoriasis, eczema, acne, and / or cancer. The therapeutic wearable device can be incorporated into wearable items such as bracelets, necklaces or garments of clothing.

The present application relates to a method for treating an autoimmune disease by an IL-17 antagonist. The present application relates to an application of an IL-17A binding agent in preparation of a drug for treating an autoimmune disease, such as rheumatoid arthritis, ankylosing spondylitis, and psoriasis, in particular, provides a method for treating inflammation or an autoimmune disease, comprising administering an effective amount of an IL-17 binding agent to a patient, wherein the administration frequency is less than once a week.

This invention provides the use of NUCB1 in the prevention and / or treatment of autoimmune diseases. Specifically, this invention provides the use of the NUCB1 gene, or its protein, or its promoter, for the preparation of compositions or formulations for the prevention and / or treatment of autoimmune diseases. The NUCB1 gene, or its protein, or its promoter of this invention can significantly prevent and / or treat autoimmune diseases, especially systemic lupus erythematosus, atopic dermatitis, rheumatoid arthritis, psoriasis, multiple sclerosis, or Crohn's disease.